> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Silgan CEO Says Prescription Pharma Products Run On Three-To-Five-Year Pipelines, 'Not Competing On Price'
- URL: https://www.bullished.co/silgan-ceo-says-prescription-pharma-products-run-on-three-to-five-year-pipelines-not-737d552b/
- Published: 2026-10-29T13:16:47.000Z
- Updated: 2026-10-29T14:47:00.000Z
- Description: Silgan's prescription pharma dispensing business is a roughly $250 million unit, and its shipments are running ahead of plan, the CEO said.
- Author: Matteo Parrino
- Tags: Earnings, SLGN, Industry: Industrials

[Silgan Holdings](https://www.bullished.co/tag/slgn/), which makes dispensing and specialty closures, metal containers and custom plastic containers, is winning pharma business on development time, not price, CEO Adam Greenlee said on the company's [third-quarter earnings call](https://markets.ft.com/data/announce/detail?dockey=600-202610290600BIZWIRE%5FUSPRX%5F%5F%5F%5F20261029%5FBW978584-1&ref=bullished.co) Thursday. He put its overall healthcare and pharma business at roughly $250 million.

## Three to five years in the making

Asked by a Jefferies analyst whether pharma works differently from Silgan's other lines, Greenlee said the products are regulated and "require significant development, significant regulatory review. These are three to five year pipelines." He said the work involves drug master files, and that what lifted the third quarter and will shape the fourth was in development for a long time.

He was blunt on pricing: "we are not competing on price, just to be super clear about that." The pitch, he said, is innovation and meeting a customer's specific needs.

Greenlee conceded that not every customer product reaches commercialization as drug trials proceed. Silgan's dispensing technology, he said, is not specific to any one drug or molecule and has broad uses.

## Shipping a little ahead of plan

Prescription pharma dispensing products grew by a double-digit percentage in North America in the quarter, Greenlee said. Responding to a Raymond James analyst, he said Silgan was probably shipping a little ahead of original expectations, but that fourth-quarter strength looks "very consistent" with the third. He expects nice growth again next year.

Longer term, he sees close to high-single-digit growth in healthcare pharma, against mid-single digits for fragrance and beauty.

## Trivium split would unmask the growth

Silgan has proposed buying Trivium, which would create two companies, Silgan DS and Silgan MCC, with a close expected in mid-2027\. Food and beverage volumes, which were soft this quarter, would move to MCC.

Greenlee said that shift should let fragrance and healthcare volumes drive the dispensing segment's results, with a higher growth rate. Alex Hutter, Silgan's senior vice president of strategy and investor relations, said healthcare is closer to 10% of the planned dispensing segment's end markets, while fragrance and personal care is about half.

Silgan said it will report full-year and fourth-quarter results after the start of the year.

Learn

- [How To Read An Earnings Call Transcript: Start With Guidance, Then Find What's Missing →](https://www.bullished.co/learn/how-to-read-an-earnings-call/)  
How to read an earnings call transcript: check guidance first, look for dropped metrics, compare growth with last quarter, and watch hedged wording.

### Sources

- [Silgan: Q3 Earnings Snapshot](https://finance.yahoo.com/markets/stocks/articles/silgan-q3-earnings-snapshot-101603737.html?ref=bullished.co) — Associated Press
- [Silgan Announces Third Quarter 2026 Results; Raises Full Year Earnings Estimate Midpoint – Company Announcement - FT.com](https://markets.ft.com/data/announce/detail?dockey=600-202610290600BIZWIRE%5FUSPRX%5F%5F%5F%5F20261029%5FBW978584-1&ref=bullished.co) — Financial Times
- [Silgan Holdings (SLGN) Tops Q3 Earnings Estimates](https://finance.yahoo.com/markets/stocks/articles/silgan-holdings-slgn-tops-q3-104506674.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [Silgan: Q3 Earnings Snapshot – WTOP News](https://wtop.com/national/2026/10/silgan-q3-earnings-snapshot/?ref=bullished.co) — wtop.com
- [Silgan: Q3 Earnings Snapshot | 9news.com](https://www.9news.com/article/syndication/associatedpress/silgan-q3-earnings-snapshot/616-175845ca-97fb-4c64-9009-659206f204f5?ref=bullished.co) — Associated Press

### More on Silgan Holdings

- [Silgan CEO Says One Soup Customer's Price Increase Hit Can Volumes, And No Rebound Is Planned](https://www.bullished.co/silgan-ceo-says-one-soup-customers-price-increase-hit-can-volumes-and-no-rebound-is-8f0500d5/)
- [Silgan To Get $2.3 Billion In Cash, Keep 60% Of New Metal Packaging Partnership With AIP](https://www.bullished.co/silgan-to-get-2-3-billion-in-cash-keep-60-of-new-metal-packaging-partnership-with-aip-04941378/)

[All Silgan Holdings (SLGN) coverage →](https://www.bullished.co/tag/slgn/)